Valencell has won a collaborative NIH award to integrate RPI’s daysimetry technology into Valencell’s Healthset® platform. This new mobile device, called the “Dayset,” will measure the user’s circadian environment and characterize the user’s physiological response to lighting conditions throughout their normal everyday lives. The ultimate goal of this research is to develop a comfortable, wearable, therapeutic device for treating jet-lag, sleep disorders, breast cancer, and more.
This collaborative research has been funded through the NIH Genes, Environment, and Health Initiative (GEI).